Investment
Features
FeesSafety
Academy
More
Pluang+

Biodexa enrolls 100 patients in Phase 3 trial for FAP treatment eRapa, advancing cancer drug development

Market News
13 Oct 2026
GlobeNewsWire
View Source
Bullish
Biodexa enrolls 100 patients in Phase 3 trial for FAP treatment eRapa, advancing cancer drug development

Biodexa Pharmaceuticals has reached a milestone by enrolling 100 patients in its Phase 3 Serenta trial testing eRapa for Familial Adenomatous Polyposis (FAP), a hereditary condition leading to colorectal cancer. The trial is active across multiple sites in the US, Europe, and soon Canada, aiming to evaluate eRapa's effectiveness in preventing disease progression. A futility analysis is expected early next year, with database lock by year-end, potentially accelerating the drug's development timeline. eRapa, an mTOR inhibitor, has orphan drug status and targets a key pathway in FAP polyps, offering a novel treatment option where none currently exist.

Biodexa's Serenta Phase 3 trial milestone is noted here with Pluang's health sector data for context. Of 128 priced health-sector US stocks on Pluang, 76 rose and 46 fell. Notable movers include Incyte Corporation at USD 109.38 with a -1.78% change and 100% buy order activity, InMode Ltd at USD 14.55 up 1.75% with 100% buy orders, and Abbott Laboratories at USD 103.60 up 1.75% with 85% sell orders. Data is as of Oct 13, 2026 18:43 WIB.

More News

New 'BadEngram' attack exposes hidden risks in open-weight AI models' memory components

New 'BadEngram' attack exposes hidden risks in open-weight AI models' memory components

Researchers from Pillar Security and Fujitsu revealed 'BadEngram,' a stealthy supply-chain attack targeting the gated memory components in open-weight AI models like Qwen3.8-Flash-Next and DeepSeek-V4.1-Flash. This attack implants a hidden backdoor b...

Market News
Bearish
50 minutes ago
Alm. Brand A/S buys back 1.07 million shares in latest week, holding 3.49% of total shares.

Alm. Brand A/S buys back 1.07 million shares in latest week, holding 3.49% of total shares.

Alm. Brand A/S continued its share buyback program from October 6 to 12, 2026, purchasing 1,067,445 shares at an average price of DKK 16.41 per share. This brings the total shares bought under the program to 16,272,795, with a cumulative spend of abo...

Company Fundamentals
Neutral
50 minutes ago
Michelin reports total voting rights and shares as of September 30, 2026, including treasury shares.

Michelin reports total voting rights and shares as of September 30, 2026, including treasury shares.

Michelin has officially declared the total number of voting rights and shares composing its capital as of September 30, 2026. The company reports 687,606,419 shares outstanding, with a theoretical total of 976,500,156 voting rights and 958,851,942 ex...

Company Fundamentals
Neutral
50 minutes ago
Michelin reports total voting rights and shares as of September 30, 2026

Michelin reports total voting rights and shares as of September 30, 2026

Michelin disclosed the total number of its shares and voting rights as of September 30, 2026. The company has 687,606,419 shares and 958,851,942 voting rights, accounting for 17,648,214 treasury shares. This disclosure is part of regulatory complianc...

Company Fundamentals
Neutral
50 minutes ago
US Rental Business Census 2026 counts 128,188 rental listings, revealing state-by-state rental market insights.

US Rental Business Census 2026 counts 128,188 rental listings, revealing state-by-state rental market insights.

The US Rental Business Census 2026 by Reservety reports 128,188 rental business listings across 12 categories in all US states and D.C., identifying about 114,235 unique businesses with 98,123 independent operators. Wyoming leads with the highest ren...

Market News
Neutral
50 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App